Loading...
XOSL
ZLNA
Market cap6mUSD
Mar 04, Last price  
2.05NOK
Name

Ultimovacs ASA

Chart & Performance

D1W1MN
XOSL:ZLNA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.51%
Rev. gr., 5y
%
Revenues
0k
Net income
-189m
L+28.82%
-28,776,000-32,269,000-53,904,000-55,851,000-116,718,000-166,757,000-146,901,000-189,239,000
CFO
-163m
L-13.92%
-31,099,000-27,225,000-50,389,000-62,989,000-108,223,000-125,828,000-167,695,000-189,827,000-163,404,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
URL
https://ultimovacs.com/
IPO date
Jun 03, 2019
Employees
24
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT